• Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
Immunicum
  • Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
You are here:HomeInvestorsPress ReleasesPress releases 2019

Investors

  • Overview
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • Subscribe
  • Events & Presentations
  • Corporate Governance
    • Articles of Association
    • General meeting
    • Board of directors
    • Corporate governance reports
    • Senior Executives
    • Nomination Committee
    • Remuneration and the remuneration committee
    • Auditors and audit committee
    • Scientific committee
    • Scientific Advisory Board
  • Shareholder & Stock Info
    • Shareholders
    • Insider
    • Investment calculator
    • Share price look-up
  • Analyst Coverage
  • Financial Reports
  • Financial calendar
  • Secured Rights issue 2018
  • Secured Rights issue 2017
  • Downloads

Press releases 2019

  • All
  • Regulatory release

Immunicum AB (publ) Announces Upcoming Oral Presentation on MERECA Trial at the ASCO-SITC Clinical Immuno-Oncology Symposium

20 December 2019 Read more

Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO

13 December 2019 Read more R

Immunicum AB (publ) Interim Report January – September 2019

6 November 2019 Read more R

Immunicum AB (publ) Announces Positive Preclinical Data on Ilixadencel in Combination with CTLA-4 Immune Checkpoint Inhibitor

21 October 2019 Read more

Immunicum AB (publ) Announces Nomination Committee for AGM 2020

14 October 2019 Read more R

Immunicum AB (publ) Announces Advancement to Next Dosage Group Level in Phase Ib/II ILIAD Combination Trial

1 October 2019 Read more

Immunicum AB (publ) Announces Complete Topline Data Analysis from Phase II MERECA Trial

25 September 2019 Read more R

Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Including Complete Tumor Responses in Metastatic Renal Cell Carcinoma Patients

29 August 2019 Read more R

Immunicum AB (publ) Interim Report January – June 2019

20 August 2019 Read more R

Immunicum AB (publ) Announces New Issuance Date for Interim Report April – June 2019 and Corporate Update Event

28 June 2019 Read more R

Immunicum AB (publ) Announces Positive Topline Results from the Phase I/II Clinical Trial in GIST

12 June 2019 Read more

Immunicum AB (publ) Announces Outcome of Subscription in Employee Incentive Program 2019/2022

28 May 2019 Read more

Immunicum AB (publ) Announces Upcoming Conferences in May and June

7 May 2019 Read more

Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2019

25 April 2019 Read more

Immunicum AB (publ) Interim Report January - March 2019

25 April 2019 Read more

Notice of Annual General Meeting in Immunicum AB (publ)

26 March 2019 Read more

Immunicum AB (publ) Year-End Report 2018

15 February 2019 Read more

Immunicum AB (publ) Announces First Patient Treated in Phase Ib/II ILIAD Combination Trial

11 February 2019 Read more

Immunicum AB (publ) Announces Upcoming Investor Events in February

1 February 2019 Read more

Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue

31 January 2019 Read more R

Changes to the Nomination Committee for Immunicum AB (publ)

30 January 2019 Read more R

Immunicum AB (publ) Announces Upcoming Investor Events in January

22 January 2019 Read more

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology

21 January 2019 Read more

Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO

13 December 2019 Read more R

Immunicum AB (publ) Interim Report January – September 2019

6 November 2019 Read more R

Immunicum AB (publ) Announces Nomination Committee for AGM 2020

14 October 2019 Read more R

Immunicum AB (publ) Announces Complete Topline Data Analysis from Phase II MERECA Trial

25 September 2019 Read more R

Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Including Complete Tumor Responses in Metastatic Renal Cell Carcinoma Patients

29 August 2019 Read more R

Immunicum AB (publ) Interim Report January – June 2019

20 August 2019 Read more R

Immunicum AB (publ) Announces New Issuance Date for Interim Report April – June 2019 and Corporate Update Event

28 June 2019 Read more R

Change in Number of Shares and Votes in Immunicum AB (publ) After Completed Rights Issue

31 January 2019 Read more R

Changes to the Nomination Committee for Immunicum AB (publ)

30 January 2019 Read more R
Press releases

Choose which language you would like to receive the press release in:

Swedish English
Contact us

Östermalmstorg 5
114 42 Stockholm
Sweden

Telephone

+46 (0)8 732 8400

Email

info@immunicum.com

For information about personal data processing at Immunicum, please see Immunicum´s Integrity Policy

Social
Links
  • Sitemap
  • Integrity and Cookie Policy

© 2002-2021 Immunicum AB. All rights reserved.

Designer mkmedia
To top

We use cookies to improve the user experience on Immunicum. Read more about Cookies

Approve